Monographs: Dosage forms: Specific monographs: Linezolid Tablets (Linezolidi compressi)2024-01
Category. Antituberculosis, antibiotic. Storage. Linezolid tablets should be kept in an airtight container and protected from light. Additional information. Strengths in the current WHO Model List of Essential Medicines (EML): 400 mg, 600 mg. Strengths in the current EML for children: 400 mg, 600 mg. Requirements Comply with the monograph for Tablets. Definition. Linezolid tablets contains not less than 90.0% and not more than 110.0% of the amount of Linezolid (C16H20FN3O4) stated on the label. Identity tests
Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms, using as the dissolution medium 900 mL of dissolution buffer, pH 6.8, TS and rotating the paddle at 50 revolutions per minute. At 30 minutes, withdraw a sample of about 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature. Dilute 1.0 mL of this solution to 50.0 mL with the dissolution buffer. Measure the absorbance as described under 1.6 Spectrophotometry in the visible and ultraviolet regions of the resulting solution in a cuvette with an optical pathlength of 10 mm at the maximum at about 251 nm, using the dissolution buffer as the blank. For each of the tablets tested, calculate the total amount of linezolid (C16H20FN3O4) in the medium using the absorptivity value of 56.0 for linezolid ( Related substances. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (3.5 μm). Use the following conditions for gradient elution:
Prepare the phosphate buffer by dissolving 1.36 g of potassium dihydrogen phosphate R in 1000 mL of water R.
Operate with a flow rate of 1.2 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 25 °C. Use a mixture of 80 volumes of phosphate buffer and 20 volumes of acetonitrile R and as diluent. For solution (1), transfer a quantity of the powdered tablets, nominally containing 80.0 mg of linezolid, into a 100 mL volumetric flask, add 50 mL of phosphate buffer, sonicate for 5 minutes with intermediate shaking, add 20 mL of acetonitrile R, and sonicate for further 10 minutes with intermediate shaking. Allow the flask to cool to room temperature, dilute to volume with phosphate buffer, mix and filter. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL with diluent. For solution (3), dilute 1.0 mL of solution (2) to 10.0 mL with diluent. For solution (4), dissolve 5.0 mg each of linezolid RS, linezolid impurity A RS and linezolid impurity D RS and dilute to 100.0 mL with diluent. Inject 10 µL each of solutions (1), (2), (3) and (4). Use the chromatogram obtained with solution (4) to identify the peaks due to linezolid, impurity A and impurity D in the chromatogram obtained with solution (1). The impurity peaks, if present, are eluted at the following relative retention times with reference to linezolid (retention time about 17 minutes): impurity G about 0.49; impurity C about 0.59; impurity H about 0.75; impurity F about 0.80; impurity J about 1.28; impurity D about 1.36; impurity B about 1.42; impurity A about 1.50; impurity K about 1.53 and impurity I about 1.66. The test is not valid unless in the chromatogram obtained with solution (4) the resolution between the peak of impurity D and the peak of impurity A is greater than 15.0. Also, the test is not valid unless in the chromatogram obtained with solution (3) the peak due to linezolid is detected with a signal-to-noise ratio of at least 20. In the chromatogram obtained with solution (1):
Assay. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm), packed with end-capped particles of silica gel, the surface of which has been modified with chemically-bonded octylsilyl groups (3.5 μm). Use the following conditions for gradient elution:
Prepare the phosphate buffer by dissolving 1.36 g of potassium dihydrogen phosphate R in 1000 mL of water R.
Operate at a flow rate of 1.2 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 254 nm. Maintain the column temperature at 25 °C. Use a mixture of 80 volumes of phosphate buffer and 20 volumes of acetonitrile R and as diluent. For solution (1), weigh and powder 20 tablets. Transfer a quantity of the powdered tablets, nominally containing 240.0 mg of linezolid, into a 200 mL volumetric flask, add 100 mL of phosphate buffer and sonicate for 5 minutes. Add 40 mL of acetonitrile R and sonicate for 10 minutes. Allow the solution to cool to room temperature, make up to volume with phosphate buffer, mix and filter. Dilute 5.0 mL of this solution to 50.0 mL with the diluent . For solution (2), dissolve 60.0 mg of linezolid RS in a 50 mL volumetric flask in 30 mL of the diluent and sonicate for 5 minutes. Allow the solution to cool to room temperature and make up to volume with the diluent. Dilute 5.0 mL of this solution to 50.0 mL with the diluent. Inject 10 μL each of solutions (1) and (2). Measure the areas of the peaks corresponding to linezolid obtained in the chromatograms of solutions (1) and (2) and calculate the percentage content of linezolid (C16H20FN3O4) using the declared content of C16H20FN3O4 in linezolid RS. Impurities. The impurities limited by the requirements of this monograph include those listed in the monograph on Linezolid, with the exception of impurity E. |